199 related articles for article (PubMed ID: 21646768)
1. [WT1 peptide-based immunotherapy for the treatment of malignancies: focusing on hematological neoplasms].
Oka Y; Tsuboi A; Nishida S; Hosen N; Nakata J; Hashii Y; Maeda T; Oji Y; Kumanogoh A; Sugiyama H
Rinsho Ketsueki; 2011 May; 52(5):235-42. PubMed ID: 21646768
[No Abstract] [Full Text] [Related]
2. WT1 peptide vaccination for the treatment of hematological malignancies: the present status and future direction.
Oka Y; Tsuboi A; Shirakata T; Hosen N; Nishida S; Oji Y; Sugiyama H
Rinsho Ketsueki; 2009 May; 50(5):352-7. PubMed ID: 19483394
[No Abstract] [Full Text] [Related]
3. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
[TBL] [Abstract][Full Text] [Related]
4. [Cellular immunotherapy for hematological malignancies].
Yasukawa M
Rinsho Ketsueki; 2008 Oct; 49(10):1460-71. PubMed ID: 18833930
[No Abstract] [Full Text] [Related]
5. [WT1 peptide-based immunotherapy].
Sugiyama H
Nihon Rinsho; 2005 Jun; 63(6):1101-9. PubMed ID: 15948398
[TBL] [Abstract][Full Text] [Related]
6. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers.
Oka Y; Tsuboi A; Elisseeva OA; Nakajima H; Fujiki F; Kawakami M; Shirakata T; Nishida S; Hosen N; Oji Y; Kawase I; Sugiyama H
ScientificWorldJournal; 2007 May; 7():649-65. PubMed ID: 17619750
[TBL] [Abstract][Full Text] [Related]
7. [WT1 peptide cancer vaccine].
Sugiyama H
Nihon Rinsho; 2017 Feb; 75(2):263-269. PubMed ID: 30562862
[TBL] [Abstract][Full Text] [Related]
8. [WT1 Class I Peptide/WT1 Class II Peptide Pulsed Dendritic Cell Therapy Efficacy in 60 Patients with a Wide Range of Advanced Cancers].
Kato Y
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1252-1255. PubMed ID: 27760951
[TBL] [Abstract][Full Text] [Related]
9. WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects.
Oka Y; Sugiyama H
Immunotherapy; 2010 Sep; 2(5):591-4. PubMed ID: 20874639
[No Abstract] [Full Text] [Related]
10. [The role of immunotherapy in the treatment of patients with hematologic neoplasms].
Rukavitsyn OA
Vopr Onkol; 2002; 48(2):186-92. PubMed ID: 12227066
[No Abstract] [Full Text] [Related]
11. [WT1-targeting cancer vaccine].
Sugiyama H
Nihon Rinsho; 2012 Dec; 70(12):2105-13. PubMed ID: 23259381
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children.
Sawada A; Inoue M; Kondo O; Yamada-Nakata K; Ishihara T; Kuwae Y; Nishikawa M; Ammori Y; Tsuboi A; Oji Y; Koyama-Sato M; Oka Y; Yasui M; Sugiyama H; Kawa K
Pediatr Blood Cancer; 2016 Feb; 63(2):234-41. PubMed ID: 26469989
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of hematological malignancies using dendritic cells.
Van de Velde AL; Berneman ZN; Van Tendeloo VF
Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
[TBL] [Abstract][Full Text] [Related]
14. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy.
Ohno S; Kyo S; Myojo S; Dohi S; Ishizaki J; Miyamoto K; Morita S; Sakamoto J; Enomoto T; Kimura T; Oka Y; Tsuboi A; Sugiyama H; Inoue M
Anticancer Res; 2009 Nov; 29(11):4779-84. PubMed ID: 20032435
[TBL] [Abstract][Full Text] [Related]
15. WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone.
Nakajima H; Kawasaki K; Oka Y; Tsuboi A; Kawakami M; Ikegame K; Hoshida Y; Fujiki F; Nakano A; Masuda T; Wu F; Taniguchi Y; Yoshihara S; Elisseeva OA; Oji Y; Ogawa H; Azuma I; Kawase I; Aozasa K; Sugiyama H
Cancer Immunol Immunother; 2004 Jul; 53(7):617-24. PubMed ID: 15175906
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.
Morita S; Oka Y; Tsuboi A; Kawakami M; Maruno M; Izumoto S; Osaki T; Taguchi T; Ueda T; Myoui A; Nishida S; Shirakata T; Ohno S; Oji Y; Aozasa K; Hatazawa J; Udaka K; Yoshikawa H; Yoshimine T; Noguchi S; Kawase I; Nakatsuka S; Sugiyama H; Sakamoto J
Jpn J Clin Oncol; 2006 Apr; 36(4):231-6. PubMed ID: 16611662
[TBL] [Abstract][Full Text] [Related]
17. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis.
Ariyaratana S; Loeb DM
Expert Rev Mol Med; 2007 May; 9(14):1-17. PubMed ID: 17524167
[TBL] [Abstract][Full Text] [Related]
18. [Peptide vaccine treatment for colorectal cancer].
Okuno K
Nihon Rinsho; 2011 Apr; 69 Suppl 3():574-8. PubMed ID: 22214026
[No Abstract] [Full Text] [Related]
19. Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.
Van Driessche A; Berneman ZN; Van Tendeloo VF
Oncologist; 2012; 17(2):250-9. PubMed ID: 22291091
[TBL] [Abstract][Full Text] [Related]
20. WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy.
Rein LA; Chao NJ
Expert Opin Investig Drugs; 2014 Mar; 23(3):417-26. PubMed ID: 24521058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]